BrainStorm Cell Therapuetics is currently launching a Phase II clinical trial utilizing mesenchymal stem cells (MSCs) that are cultured to develop into neurological components able to treat progressive multiple sclerosis (MS). The proprietary technology called NurOwn uses a patient’s own (autologous) MSCs that are modified outside of the body and returned to repair and support neurons that are attacked in patients with MS. The stem cells are modified to produce growth factors, which support neurons and enhance differentiation and survival of neural cells.
A team of researchers at the Hadassah Medical Center in Israel has developed a unique method of applying a patient’s own stem cells to restore mobility following progressive multiple sclerosis (MS). MS is an autoimmune disorder in which the body attacks its own neurons and affects millions of people worldwide. Severely progressive MS leads to complete loss of limb function, memory problems, seizures, and even systemic organ failure. This groundbreaking, double-blind, Phase II clinical trial successfully administered autologous (the patient’s own) mesenchymal stem cells, which were cultured and expanded to clinically significant numbers, and then applied directly into the spinal fluid. The treatment simultaneously addressed the two problems of MS - inflammatory immune response and the destruction of the outer coating of neurons that allows for quick signal transduction thereby engendering a significant increase in efficacy.
Researchers in India have used an autologous stem cell treatment in a pilot pre-clinical study to completely reverse the adverse effects of a quickly progressing case of MS (multiple sclerosis). MS is an autoimmune disorder in which the body attacks its own nervous system by breaking down the myelin sheath on neurons. Proper myelination is responsible for faster transmission of nerve signals and aggressive forms of MS cause patients to lose motor functions in their limbs, as well as experience memory and cognition problems. The patient in this study was experiencing a particularly degenerative form of MS, with multiple relapses over the years, and he began losing his ability to walk. After receiving an injection of his own mesenchymal stem cells (the same type of stem cells found in teeth), as well as a monitored diet and physical therapy, the patient experienced immediate improvement. He was soon able to walk and even run again, which he had been unable to do for over five years.
Researchers from Imperial College London, led by Dr. Paolo Muraro, have refined a stem cell treatment for Multiple Sclerosis (MS); using the patient’s own stem cells to reset the immune system and “freeze” the disease. MS is a disease in which the body’s immune system attacks the protective sheath (myelin) that covers nerve fibers thereby causing communication disruptions between the brain and the rest of the body. The treatment works by first recovering healthy stem cells from the patient and then, using high-dose chemotherapy to kill the remaining damaged immune cells. Reintroducing the recovered stem cells into the patient’s body reboots the immune system and halts the disease.
Researchers at the Colorado Blood Cancer Institute have devised a successful, long-term treatment for relapsing/remitting multiple sclerosis (RRMS). The treatment approach seeks to ‘reboot’ the patient’s immune system by effectively erasing it and then rebooting it using the patient’s own [autologous] stem cells. The treatment resulted in a disease reversal rate of 86% and halted progression rate of 91% in patients participating in the study. Study patients underwent immunosuppressive therapy for up to four weeks, after which autologous stem cells were re-infused to restore a healthy immune systems. Patients were then followed for up to five years.
In a recently published study, a team of researchers led by Dr. Giovanni Mancardi from the University of Genoa conducted a phase II clinical trial to compare the effectiveness of conventional multiple sclerosis [MS] therapy to intravenous stem cell transplantation. Throughout the four year trial, the team found that, in addition to significantly decreasing disease progression and brain damage compared to MS drug mitoxantrone [MTX], the transplanted stem cells had migrated into the patients’ bone marrow and stimulated the generation of new, non-harmful immune cells, essentially resetting the immune system.
The Multiple Sclerosis Society of Canada has funded Canada’s first stem cell clinical trial to treat multiple sclerosis, conducted by researchers at the University of Ottawa. The trial, called MESCAMS [Mesenchymal Stem Cell Therapy for Canadian MS patients], will comprise MSC infusions to the central nervous system to utilize their ability to regulate autoimmune attacks and reduce inflammation in 40 MS patients.
Topics: ALS, Phase III, neural stem cells, multiple sclerosis, Brain, clinical trials, Debilitating Diseases, Stemcells, autologousstemcells, Amyotrophic lateral sclerosis, Neurodegenerative disease, stemsaveblog
In a recent update of an ongoing five year clinical trial conducted by the Chicago Blood Cancer Institute, patients with relapsing-remitting multiple sclerosis have experienced suppression of disease-related inflammation as a result of hematopoietic stem cell transplantations. The stem cells have the ability to regulate the autoimmune attack on the central nervous system, and have provided 82.8% of the patients with two years thus far of event-free disease remission.
A recent clinical trial conducted by the University of Genoa has determined that mesenchymal stem cell therapy to treat multiple sclerosis is indeed safe to perform on humans. 27 MS patients completed the study, which comprised an injection of the patient’s own [autologous] mesenchymal stem cells [MSCs] to reduce excessive inflammation caused by the patients’ own immune systems. None of the patients suffered any side effects from the injection.
Topics: limbs, Phase III, traumatic brain injuries, neural stem cells, multiple sclerosis, clinical trials, Debilitating Diseases, Phase II, Stemcells, autologousstemcells, Neurodegenerative disease, stemsaveblog
As reported on the front page of the New York Times Science section, clinical applications of stem cell based therapies are accelerating at a rate that will revolutionize the medical field in a matter of years. In the United States alone, there are currently over 4000 therapies in clinical trials for the treatment of heart disease, blindness, spinal cord injuries, diabetes, H.I.V., and other diseases, injuries, and traumas.
Topics: Muscular Dystrophy, ALS, Parkinson's, Phase III, multiple sclerosis, Heart, Joints, Alzheimer's, burn injuries, Diabetes, Acute Myocardial Infarction, Brain, Heart Failure, clinical trials, Bone, Debilitating Diseases, Phase II, Arthritis, Stemcells, Teeth, autologousstemcells, cartilage, Amyotrophic lateral sclerosis, Brain Tumors, Blindness, stemsaveblog